Literature DB >> 11124893

Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2.

C Knott1, G Stern, G P Wilkin.   

Abstract

Degeneration of dopaminergic neurons and focal gliosis are pathological hallmarks of Parkinson's disease and although the brain is described as immune-privileged focal immune reactions surround failing nigral neurons. We examined the cellular distribution of pro- and anti-inflammatory molecules in human parkinsonian and neurologically normal substantia nigra and caudate-putamen postmortem. An up-regulation of nitric oxide synthase- and cyclo-oxygenase-1- and -2-containing amoeboid microglia was found in parkinsonian but not control nigra. Astroglia contained low levels of these molecules in both groups. Lipocortin-1-immunoreactive amoeboid microglia were present within the astrocytic envelope of neurons adjacent to or within glial scars in parkinsonian nigra only. Lipocortin-1 is known to have neuroprotective and anti-inflammatory properties. Up-regulation of nitric oxide synthase is generally associated with neurodestruction whereas prostaglandin synthesis may be either neurodestructive or protective. The balance of these molecules is likely to be decisive in determining neuronal survival or demise.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11124893     DOI: 10.1006/mcne.2000.0914

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  142 in total

Review 1.  Glial cell response: A pathogenic factor in Parkinson's disease.

Authors:  Du Chu Wu; Kim Tieu; Oren Cohen; Dong-Kug Choi; Miquel Vila; Vernice Jackson-Lewis; Peter Teismann; Serge Przedborski
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

2.  Involvement of nitric oxide in maneb- and paraquat-induced Parkinson's disease phenotype in mouse: is there any link with lipid peroxidation?

Authors:  Satya Prakash Gupta; Suman Patel; Sharawan Yadav; Anand Kumar Singh; Seema Singh; Mahendra Pratap Singh
Journal:  Neurochem Res       Date:  2010-05-09       Impact factor: 3.996

3.  Impact of endogenous nitric oxide on microglial cell energy metabolism and labile iron pool.

Authors:  Benoît Chénais; Hamid Morjani; Jean-Claude Drapier
Journal:  J Neurochem       Date:  2002-05       Impact factor: 5.372

Review 4.  NSAIDs in the treatment and/or prevention of neurological disorders.

Authors:  Parto S Khansari; Leanne Coyne
Journal:  Inflammopharmacology       Date:  2012-01-10       Impact factor: 4.473

Review 5.  Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research.

Authors:  J M Pavon; H E Whitson; M S Okun
Journal:  Maturitas       Date:  2010-02-01       Impact factor: 4.342

6.  A model of nitric oxide induced α-synuclein misfolding in Parkinson's disease.

Authors:  David K Stone; Tomomi Kiyota; R Lee Mosley; Howard E Gendelman
Journal:  Neurosci Lett       Date:  2012-07-07       Impact factor: 3.046

7.  Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease.

Authors:  Chi Wang Ip; Sandra K Beck; Jens Volkmann
Journal:  J Neural Transm (Vienna)       Date:  2015-08-20       Impact factor: 3.575

8.  Translocator protein 18 kDa negatively regulates inflammation in microglia.

Authors:  Keun-Ryung Bae; Hyun-Jung Shim; Deebika Balu; Sang Ryong Kim; Seong-Woon Yu
Journal:  J Neuroimmune Pharmacol       Date:  2014-04-01       Impact factor: 4.147

Review 9.  L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease.

Authors:  Norio Ogawa; Masato Asanuma; Ikuko Miyazaki; Francisco J Diaz-Corrales; Ko Miyoshi
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

Review 10.  Intrinsic regulation of brain inflammatory responses.

Authors:  Elena Galea; Michael T Heneka; Cinzia Dello Russo; Douglas L Feinstein
Journal:  Cell Mol Neurobiol       Date:  2003-10       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.